These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 18549892

  • 21. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
    Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, Kim SW, Shin CS, Kim SY.
    PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
    [Abstract] [Full Text] [Related]

  • 22. Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms.
    Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, Zermani R.
    Tunis Med; 2013 Mar; 91(3):209-15. PubMed ID: 23588637
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pheochromocytomas: can malignant potential be predicted?
    John H, Ziegler WH, Hauri D, Jaeger P.
    Urology; 1999 Apr; 53(4):679-83. PubMed ID: 10197840
    [Abstract] [Full Text] [Related]

  • 25. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, Nomine C, Lomazzi S, Vignaud JM, Weryha G, Oussalah A, Gauchotte G, Busby-Venner H.
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [Abstract] [Full Text] [Related]

  • 26. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.
    Stenman A, Svahn F, Hojjat-Farsangi M, Zedenius J, Söderkvist P, Gimm O, Larsson C, Juhlin CC.
    Am J Surg Pathol; 2019 Mar; 43(3):409-421. PubMed ID: 30451732
    [Abstract] [Full Text] [Related]

  • 27. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
    Parasiliti-Caprino M, Lucatello B, Lopez C, Burrello J, Maletta F, Mistrangelo M, Migliore E, Tassone F, La Grotta A, Pia A, Reimondo G, Giordano R, Giraudo G, Piovesan A, Ciccone G, Deandreis D, Limone P, Orlandi F, Borretta G, Volante M, Mulatero P, Papotti M, Aimaretti G, Terzolo M, Morino M, Pasini B, Veglio F, Ghigo E, Arvat E, Maccario M.
    Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
    [Abstract] [Full Text] [Related]

  • 28. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
    Tavangar SM, Shojaee A, Moradi Tabriz H, Haghpanah V, Larijani B, Heshmat R, Lashkari A, Azimi S.
    Pathol Res Pract; 2010 May 15; 206(5):305-9. PubMed ID: 20189725
    [Abstract] [Full Text] [Related]

  • 29. Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients.
    Ocal I, Avci A, Cakalagaoglu F, Can H.
    Asian Pac J Cancer Prev; 2014 May 15; 15(4):1751-5. PubMed ID: 24641403
    [Abstract] [Full Text] [Related]

  • 30. Elevated levels of telomerase activity in malignant pheochromocytoma.
    Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K.
    Cancer; 1998 Jan 01; 82(1):176-9. PubMed ID: 9428495
    [Abstract] [Full Text] [Related]

  • 31. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
    Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA.
    J Clin Oncol; 1989 Nov 01; 7(11):1720-5. PubMed ID: 2809684
    [Abstract] [Full Text] [Related]

  • 32. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z, Lloyd RV.
    Adv Anat Pathol; 2015 Sep 01; 22(5):283-93. PubMed ID: 26262510
    [Abstract] [Full Text] [Related]

  • 33. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
    Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stålberg P, Khanafshar E, Shibru D, Duh QY, Clark OH, Kebebew E, Gill AJ, Clifton-Bligh R, Robinson BG, Benn DE, Sidhu SB.
    Endocr Relat Cancer; 2010 Sep 01; 17(3):835-46. PubMed ID: 20621999
    [Abstract] [Full Text] [Related]

  • 34. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
    Thouënnon E, Elkahloun AG, Guillemot J, Gimenez-Roqueplo AP, Bertherat J, Pierre A, Ghzili H, Grumolato L, Muresan M, Klein M, Lefebvre H, Ouafik L, Vaudry H, Plouin PF, Yon L, Anouar Y.
    J Clin Endocrinol Metab; 2007 Dec 01; 92(12):4865-72. PubMed ID: 17878247
    [Abstract] [Full Text] [Related]

  • 35. Clinical experience over 48 years with pheochromocytoma.
    Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW.
    Ann Surg; 1999 Jun 01; 229(6):755-64; discussion 764-6. PubMed ID: 10363888
    [Abstract] [Full Text] [Related]

  • 36. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas.
    August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, Kersting C, Buerger H.
    Mod Pathol; 2004 Sep 01; 17(9):1119-28. PubMed ID: 15167935
    [Abstract] [Full Text] [Related]

  • 37. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas.
    Petri BJ, Speel EJ, Korpershoek E, Claessen SM, van Nederveen FH, Giesen V, Dannenberg H, van der Harst E, Dinjens WN, de Krijger RR.
    Mod Pathol; 2008 Apr 01; 21(4):407-13. PubMed ID: 18223555
    [Abstract] [Full Text] [Related]

  • 38. Phosphorylated histone H3, Ki-67, p21, fatty acid synthase, and cleaved caspase-3 expression in benign and atypical granular cell tumors.
    Kapur P, Rakheja D, Balani JP, Roy LC, Amirkhan RH, Hoang MP.
    Arch Pathol Lab Med; 2007 Jan 01; 131(1):57-64. PubMed ID: 17227124
    [Abstract] [Full Text] [Related]

  • 39. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A, Zedenius J, Juhlin CC.
    Surgery; 2019 Nov 01; 166(5):901-906. PubMed ID: 31239074
    [Abstract] [Full Text] [Related]

  • 40. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y, Gao X, Pecori A, Nakamura Y, Tezuka Y, Omata K, Ono Y, Morimoto R, Satoh F, Sasano H.
    Front Endocrinol (Lausanne); 2020 Nov 01; 11():587769. PubMed ID: 33193100
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.